Page last updated: 2024-09-04

mk 767 and Diabetes Mellitus, Type 2

mk 767 has been researched along with Diabetes Mellitus, Type 2 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL	1
Henke, BR	1
Calkin, AC; Cooper, ME; Thomas, MC	1
Narce, M; Poisson, JP	1

Reviews

2 review(s) available for mk 767 and Diabetes Mellitus, Type 2

Article	Year
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17 Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2004
MK-767. Kyorin/Banyu/Merck. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:4 Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidines	2003

Other Studies

2 other study(ies) available for mk 767 and Diabetes Mellitus, Type 2

Article	Year
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. Journal of medicinal chemistry, 2001, Jun-21, Volume: 44, Issue:13 Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides	2001
Novel PPARgamma-dependent and independent effects for thiazolidinediones. Current opinion in lipidology, 2003, Volume: 14, Issue:6 Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha	2003

Article

Year

Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.

Journal of medicinal chemistry, 2001, Jun-21, Volume: 44, Issue:13

Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides

2001

Novel PPARgamma-dependent and independent effects for thiazolidinediones.

Current opinion in lipidology, 2003, Volume: 14, Issue:6

Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha

2003